GLP-1受体激动剂对2型糖尿病患者心肌及血管舒张功能的影响  

Effects of GLP-1 receptor agonist on myocardial and vascular diastolic function in patients with type 2 diabetes

作　　者：邵亚丽 张计划 吴燕 刘志郎 Shao Yali;Zhang Jihua;Wu Yan;Liu Zhilang(Shan County Central Hospital,Heze,Shandong 274300,China)

机构地区：[1]山东省单县中心医院,山东菏泽274300

出　　处：《首都食品与医药》2023年第11期59-62,共4页Capital Food Medicine

摘　　要：目的探讨胰高血糖素样肽-1(GLP-1)受体激动剂对2型糖尿病患者心肌及血管舒张功能的影响.方法选取2021年1月-2022年12月收治的80例2型糖尿病患者作为研究对象,用随机数字表法将其分为对照组和观察组,每组各40例,对照组接受二甲双胍联合门冬胰岛素30治疗,观察组接受二甲双胍联合GLP-1受体激动剂治疗,比较两组患者血糖指标、血脂、心脏功能、血管舒张功能、不良反应发生率等.结果治疗前组间比较血糖指标,P>0.05,治疗后,观察组HbA1c、2hPG、FBG低于对照组(P<0.05);治疗前组间比较血脂指标,P>0.05,治疗后,观察组LDL-C、TG、TC低于对照组,HDL-C高于对照组(P<0.05);治疗前组间比较LVEF、血管舒张率水平,P>0.05,治疗后,观察组LVEF、肱动脉血管舒张率高于对照组(P<0.05);治疗前组间比较体重指数,P>0.05,治疗后,观察组体重指数低于对照组(P<0.05);比较两组不良反应发生率(5.00%vs7.50%),差异无统计学意义(P>0.05).结论GLP-1受体激动剂治疗2型糖尿病,能更好地控制机体血糖、血脂水平,保护心血管,疗效理想.Objective To investigate the effect of glucagon like peptide-1(GLP-1)receptor agonist on myocardial and vascular diastolic function in patients with type 2 diabetes.M ethods 80 patients with type 2 diabetes admitted from January 2021 toD ecember 2022 were selected as the research objects,and they were randomly dividde into a control group and an observation group with 40 patienst in each group.The control group received metformin combined with insuinl aspart 30,and the observation group received metformin combined with GLP-1 receptor agonist.The blood glucose index,blood lipids,cardiac function,vasodilation function,and the incidence of adverse reactions of the two groups were compared.R esults Compared with the blood glucose index,theP value between the groups before treatment was>0.05.After treatment,the HbA1c,2hPG and FBGn i the observation group were lower than those in the control gorup(P<0.05).Compared with the indexes of blood lipids,thPe value between the groups before treatment was>0.05.After treatment,the LDL-C,TG and TC in the observation group were lower than those in the control group,while the HDL-C was higher than that int he control group P(<0.05).Compared the LVEF and vasodilation rate,theP value between the groups before treatment was>0.05.Afte r treatment,the LVEF and brachial artery vasodilation rate in the observation group wa shigher than that in the control groupP(<0.05).Compared with the body mass index,theP value between the groups before treatment was>0.05,and aftetrr eatment,the body weight of the observation group was lower than that of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions(5.00%vs7.50%).Conclusion GLP-1 receptor agonist can better control the blood sugar and blood lipid of the body,protect the cardiovascular system,and has an ideal effect in the treatment of type 2 diabetes.

关 键 词：2型糖尿病 GLP-1受体激动剂 血糖 血脂 心肌 血管舒张功能 

分 类 号：R587.1[医药卫生—内分泌]